# Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

> **NCT03440385** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 606 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ozanimod
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03440385
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-07
- **Primary completion:** 2023-11-21
- **Final completion:** 2023-11-21
- **Target enrollment:** 606 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03440385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03440385, "Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03440385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*